Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A EUROPEAN, MULTICENTRE, PHASE II/III RANDOMISED DOUBLE-BLIND, PLACEBO CONTROLLED STUDY EVALUATING LANREOTIDE AS MAINTENANCE THERAPY IN PATIENTS WITH NON-RESECTABLE DUODENO-PANCREATIC NEUROENDOCRINE TUMOURS AFTER FIRST-LINE TREATMENT
Brief Summary: This European, prospective, multicentre, double-blind randomised study will evaluate the effect of lanreotide (120 mg every 28 days until disease progression) versus placebo in patients with metastatic/locally advanced, non-resectable, duodeno-pancreatic neuroendocrine tumours.


Options:
A: Arm Label: 177Lu-DOTA-EB-TATE 1; Type: EXPERIMENTAL; Interventions: Drug: 177Lu-DOTA-EB-TATE 1 | Arm Label: 177Lu-DOTA-EB-TATE 2; Type: EXPERIMENTAL; Interventions: Drug: 177Lu-DOTA-EB-TATE 2 | Arm Label: 177Lu-DOTA-EB-TATE 3; Type: EXPERIMENTAL; Interventions: Drug: 177Lu-DOTA-EB-TATE 3 | Arm Label: 177Lu-DOTA-TATE; Type: EXPERIMENTAL; Interventions: Drug: 177Lu-DOTA-TATE | Arm Label: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine); Type: EXPERIMENTAL; Interventions: Drug: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine) | Arm Label: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine); Type: EXPERIMENTAL; Interventions: Drug: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine) | Intervention Type: DRUG; Name: 177Lu-DOTA-EB-TATE 1; Assigned to Arm(s): 177Lu-DOTA-EB-TATE 1 | Intervention Type: DRUG; Name: 177Lu-DOTA-TATE; Assigned to Arm(s): 177Lu-DOTA-TATE | Intervention Type: DRUG; Name: 177Lu-DOTA-EB-TATE 2; Assigned to Arm(s): 177Lu-DOTA-EB-TATE 2 | Intervention Type: DRUG; Name: 177Lu-DOTA-EB-TATE 3; Assigned to Arm(s): 177Lu-DOTA-EB-TATE 3 | Intervention Type: DRUG; Name: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine); Assigned to Arm(s): 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE with amino acids (lysine and arginine) | Intervention Type: DRUG; Name: 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine); Assigned to Arm(s): 3.7 GBq (100 mCi) of 177Lu-DOTA-EB-TATE without amino acids (lysine and arginine)
B: Arm Label: 250 mg Telotristat Etiprate; Type: EXPERIMENTAL; Interventions: Drug: Telotristat etiprate, Drug: Placebo-matching telotristat etiprate | Arm Label: 500 mg Telotristat Etiprate; Type: EXPERIMENTAL; Interventions: Drug: Telotristat etiprate, Drug: Placebo-matching telotristat etiprate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo-matching telotristat etiprate | Arm Label: Telotristat Etiprate Open-Label Extension; Type: EXPERIMENTAL; Interventions: Drug: Telotristat etiprate, Drug: Placebo-matching telotristat etiprate | Intervention Type: DRUG; Name: Telotristat etiprate; Assigned to Arm(s): 250 mg Telotristat Etiprate, 500 mg Telotristat Etiprate, Telotristat Etiprate Open-Label Extension | Intervention Type: DRUG; Name: Placebo-matching telotristat etiprate; Assigned to Arm(s): 250 mg Telotristat Etiprate, 500 mg Telotristat Etiprate, Placebo, Telotristat Etiprate Open-Label Extension
C: Arm Label: Octreotide+ Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Octreotide, Drug: Everolimus | Arm Label: Octreotide+ Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Octreotide, Drug: Placebo | Intervention Type: DRUG; Name: Octreotide; Assigned to Arm(s): Octreotide+ Everolimus, Octreotide+ Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Octreotide+ Placebo | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Octreotide+ Everolimus
D: Arm Label: lanreotide; Type: EXPERIMENTAL; Interventions: Drug: lanreotide | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: lanreotide; Assigned to Arm(s): lanreotide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo

Answer: D